Literature DB >> 3824437

Protein binding of ceftriaxone: comparison of three techniques of determination and the effect of 2-hydroxybenzoylglycine, a drug-binding inhibitor in uremia.

C Fiset, F Vallée, M LeBel, M G Bergeron.   

Abstract

Ceftriaxone is a third-generation cephalosporin exhibiting a long half-life and a concentration-dependent protein binding. This study compared three techniques of protein binding determination (equilibrium dialysis chamber, ultrafiltration cones (Centriflo), and ultrafiltration (Centrifree micro-partition system) on human plasma and serum at ceftriaxone concentrations achieved clinically. A second objective was to determine the effect of 2-hydroxybenzoylglycine (HBG) on the protein binding of ceftriaxone. High performance liquid chromatography (HPLC) and liquid scintillation counting assays were used. Equilibrium dialysis was rotated for 12 h. The supplier's recommendations were followed for ultrafiltration techniques. The plasma protein binding of ceftriaxone, as determined by equilibrium dialysis and assayed by HPLC, decreased from 98.6 to 73.5% for drug concentrations varying from 25 to 400 micrograms/ml. Somewhat lower values were obtained with Centrifree, the binding fell from 92.1 to 73.5% for the same concentration range. Serum protein binding was similar to results obtained with plasma samples. Centriflo cones yielded more inconsistent results. A significant difference was seen between the three techniques (p less than 0.0001, three-way analysis of variance). The addition of HBG, a compound that inhibits drug binding in uremia, resulted in ceftriaxone binding defects similar to those seen in uremic serum. Although equilibrium dialysis remains a classic method of protein binding determination, Centrifree appears to be a better system.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3824437

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  8 in total

1.  Effects of supraphysiologic temperature and broth dilution on serum protein binding.

Authors:  R L White; M B Kays; T A Armstrong; L V Friedrich
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

Review 2.  Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.

Authors:  Harriet M Lamb; Douglas Ormrod; Lesley J Scott; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 3.  Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration.

Authors:  R N Brogden; A Ward
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

4.  Influence of assay methodology on the measurement of free serum ceftriaxone concentrations.

Authors:  S J Kohlhepp; D N Gilbert; J E Leggett
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

5.  Protein binding characteristics and pharmacokinetics of ceftriaxone in intensive care unit patients.

Authors:  Michael Schleibinger; Cathérine L Steinbach; Christoph Töpper; Alexander Kratzer; Uwe Liebchen; Frieder Kees; Bernd Salzberger; Martin G Kees
Journal:  Br J Clin Pharmacol       Date:  2015-06-11       Impact factor: 4.335

6.  Inhibitory effect of free fatty acids on plasma protein binding of disopyramide in haemodialysis patients.

Authors:  T Horiuchi; I Johno; T Hasegawa; S Kitazawa; M Goto; T Hata
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

7.  Pharmacokinetic evaluation of ceftiofur in serum, tissue chamber fluid and bronchial secretions from healthy beef-bred calves.

Authors:  S L Halstead; R D Walker; J C Baker; R E Holland; G E Stein; J G Hauptman
Journal:  Can J Vet Res       Date:  1992-10       Impact factor: 1.310

8.  Comparative study of pharmacokinetics and serum bactericidal activity of ceftizoxime and cefotaxime.

Authors:  F Vallée; M LeBel
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.